Efficacy and safety of tiotropium and olodaterol in COPD

Long-acting bronchodilators are the cornerstone of pharmacologic treatment of COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) has been introduced as fist line therapy for COPD. This article analyses the evid...

Descripción completa

Detalles Bibliográficos
Autores: Miravitlles, Marc|||0000-0002-9850-9520, Urrútia, Gerard|||0000-0002-8850-0960, Mathioudakis, Alexander G.|||0000-0002-4675-9616, Ancochea, Julio|||0000-0001-7451-4133
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:254050
Acceso en línea:https://ddd.uab.cat/record/254050
https://dx.doi.org/urn:doi:10.1186/s12931-017-0683-x
Access Level:acceso abierto
Palabra clave:Systematic review
Metanalysis
COPD
Tiotropium
Olodaterol
Tiotropium/olodaterol fixed dose combination
id ES_830762da86b9240902dfd4e6b70ed8e5
oai_identifier_str oai:ddd.uab.cat:254050
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and safety of tiotropium and olodaterol in COPDa systematic review and meta-analysisMiravitlles, Marc|||0000-0002-9850-9520Urrútia, Gerard|||0000-0002-8850-0960Mathioudakis, Alexander G.|||0000-0002-4675-9616Ancochea, Julio|||0000-0001-7451-4133Systematic reviewMetanalysisCOPDTiotropiumOlodaterolTiotropium/olodaterol fixed dose combinationLong-acting bronchodilators are the cornerstone of pharmacologic treatment of COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) has been introduced as fist line therapy for COPD. This article analyses the evidence of efficacy and safety of the TIO/OLO combination. A systematic review and metaanalysis of randomized controlled trials (RCT) with a period of treatment of at least 6 weeks, in patients with COPD confirmed by spirometry, comparing combined treatment with TIO/OLO (approved doses only), with any of the mono-components or any other active comparator administered as an inhalator. A total of 10 Randomized controlled trials (RCT) were identified (N = 10,918). TIO/OLO significantly improved trough FEV from baseline to week 12 versus TIO, OLO and LABA/ICS (0.06 L, 0.09 L and between 0.04 and 0.05 L, respectively). TIO/OLO improved transitional dyspnea index (TDI) and St. George's Respiratory Questionnaire (SGRQ) compared with mono-components, with patients more likely to achieve clinically important improvements in TDI (risk ratio [RR]: 1.17, 95% confidence interval [CI]: [1.07, 1.28] versus TIO and RR: 1.14, 95%CI: [1.01, 1.28] versus OLO) and in SGRQ (RR: 1.21, 95%CI: [1.12, 1.30] versus TIO and RR: 1.28, 95%CI: [1.18, 1.40] versus OLO). Patients treated with TIO/OLO showed a significant reduction in the use of rescue medication and no significant differences in frequency of general and serious adverse events were observed between TIO/OLO and mono-components. Treatment with TIO/OLO provided significant improvements in lung function versus mono-components and LABA/ICS with more patients achieving significant improvements in dyspnea and health status. No differences in adverse events were observed compared with other active treatments. PROSPERO register of systematic reviews (). The online version of this article (10.1186/s12931-017-0683-x) contains supplementary material, which is available to authorized users.Universitat Autònoma de Barcelona 22017-01-0120172017-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/254050https://dx.doi.org/urn:doi:10.1186/s12931-017-0683-xreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2540502026-06-06T12:50:31Z
dc.title.none.fl_str_mv Efficacy and safety of tiotropium and olodaterol in COPD
a systematic review and meta-analysis
title Efficacy and safety of tiotropium and olodaterol in COPD
spellingShingle Efficacy and safety of tiotropium and olodaterol in COPD
Miravitlles, Marc|||0000-0002-9850-9520
Systematic review
Metanalysis
COPD
Tiotropium
Olodaterol
Tiotropium/olodaterol fixed dose combination
title_short Efficacy and safety of tiotropium and olodaterol in COPD
title_full Efficacy and safety of tiotropium and olodaterol in COPD
title_fullStr Efficacy and safety of tiotropium and olodaterol in COPD
title_full_unstemmed Efficacy and safety of tiotropium and olodaterol in COPD
title_sort Efficacy and safety of tiotropium and olodaterol in COPD
dc.creator.none.fl_str_mv Miravitlles, Marc|||0000-0002-9850-9520
Urrútia, Gerard|||0000-0002-8850-0960
Mathioudakis, Alexander G.|||0000-0002-4675-9616
Ancochea, Julio|||0000-0001-7451-4133
author Miravitlles, Marc|||0000-0002-9850-9520
author_facet Miravitlles, Marc|||0000-0002-9850-9520
Urrútia, Gerard|||0000-0002-8850-0960
Mathioudakis, Alexander G.|||0000-0002-4675-9616
Ancochea, Julio|||0000-0001-7451-4133
author_role author
author2 Urrútia, Gerard|||0000-0002-8850-0960
Mathioudakis, Alexander G.|||0000-0002-4675-9616
Ancochea, Julio|||0000-0001-7451-4133
author2_role author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Systematic review
Metanalysis
COPD
Tiotropium
Olodaterol
Tiotropium/olodaterol fixed dose combination
topic Systematic review
Metanalysis
COPD
Tiotropium
Olodaterol
Tiotropium/olodaterol fixed dose combination
description Long-acting bronchodilators are the cornerstone of pharmacologic treatment of COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) has been introduced as fist line therapy for COPD. This article analyses the evidence of efficacy and safety of the TIO/OLO combination. A systematic review and metaanalysis of randomized controlled trials (RCT) with a period of treatment of at least 6 weeks, in patients with COPD confirmed by spirometry, comparing combined treatment with TIO/OLO (approved doses only), with any of the mono-components or any other active comparator administered as an inhalator. A total of 10 Randomized controlled trials (RCT) were identified (N = 10,918). TIO/OLO significantly improved trough FEV from baseline to week 12 versus TIO, OLO and LABA/ICS (0.06 L, 0.09 L and between 0.04 and 0.05 L, respectively). TIO/OLO improved transitional dyspnea index (TDI) and St. George's Respiratory Questionnaire (SGRQ) compared with mono-components, with patients more likely to achieve clinically important improvements in TDI (risk ratio [RR]: 1.17, 95% confidence interval [CI]: [1.07, 1.28] versus TIO and RR: 1.14, 95%CI: [1.01, 1.28] versus OLO) and in SGRQ (RR: 1.21, 95%CI: [1.12, 1.30] versus TIO and RR: 1.28, 95%CI: [1.18, 1.40] versus OLO). Patients treated with TIO/OLO showed a significant reduction in the use of rescue medication and no significant differences in frequency of general and serious adverse events were observed between TIO/OLO and mono-components. Treatment with TIO/OLO provided significant improvements in lung function versus mono-components and LABA/ICS with more patients achieving significant improvements in dyspnea and health status. No differences in adverse events were observed compared with other active treatments. PROSPERO register of systematic reviews (). The online version of this article (10.1186/s12931-017-0683-x) contains supplementary material, which is available to authorized users.
publishDate 2017
dc.date.none.fl_str_mv 2
2017-01-01
2017
2017-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/254050
https://dx.doi.org/urn:doi:10.1186/s12931-017-0683-x
url https://ddd.uab.cat/record/254050
https://dx.doi.org/urn:doi:10.1186/s12931-017-0683-x
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412104033796096
score 15,812429

Similares en LA Referencia